메뉴 건너뛰기
Current Oncology Reports
Volumn 5, Issue 4, 2003, Pages 263-264
Limitations to the use of the CA-125 antigen level in ovarian cancer
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CYTOTOXIC AGENT; TUMOR MARKER;
EID: 0037658635     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0063-1     Document Type: Editorial
Times cited : (10)
References (7)
  • 1
    • 0030968462 scopus 로고    scopus 로고
    • The role of CA-125 in the management of ovarian cancer
    • Markman M: The role of CA-125 in the management of ovarian cancer. Oncologist 1997, 2:6-9.
    • (1997) Oncologist , vol.2 , pp. 6-9
    • Markman, M.1
  • 2
    • 0029961618 scopus 로고    scopus 로고
    • Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
    • Rustin GJS, Nelstrop AE, McClean P, et al.: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996, 14:1545-1551.
    • (1996) J. Clin. Oncol. , vol.14 , pp. 1545-1551
    • Rustin, G.J.S.1    Nelstrop, A.E.2    McClean, P.3
  • 3
    • 0032978688 scopus 로고    scopus 로고
    • Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel
    • Bridgewater JA, Nelstrop AE, Rustin GJS, et al.: Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999, 17:501-508.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 501-508
    • Bridgewater, J.A.1    Nelstrop, A.E.2    Rustin, G.J.S.3
  • 4
    • 0030039147 scopus 로고    scopus 로고
    • Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study
    • Rustin GJS, Nelstrop AE, Tuxen MK, et al.: Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann Oncol 1996, 7:361-364.
    • (1996) Ann. Oncol. , vol.7 , pp. 361-364
    • Rustin, G.J.S.1    Nelstrop, A.E.2    Tuxen, M.K.3
  • 5
    • 0024518775 scopus 로고
    • Serum CA-125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
    • Rubin SC, Hoskins WJ, Hakes TB, et al.: Serum CA-125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989, 160:667-671.
    • (1989) Am. J. Obstet. Gynecol. , vol.160 , pp. 667-671
    • Rubin, S.C.1    Hoskins, W.J.2    Hakes, T.B.3
  • 6
    • 0022646333 scopus 로고
    • CA 125 surveillance and second-look laparotomy in ovarian carcinoma
    • Atack DB, Nisker JA, Allen HH, et al.: CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 1986, 154:287-289.
    • (1986) Am. J. Obstet. Gynecol. , vol.154 , pp. 287-289
    • Atack, D.B.1    Nisker, J.A.2    Allen, H.H.3
  • 7
    • 0028631081 scopus 로고
    • Follow-up of the asymptomatic patient with ovarian cancer
    • Markman M: Follow-up of the asymptomatic patient with ovarian cancer. Gynecol Oncol 1994, 55:S134-S137.
    • (1994) Gynecol. Oncol. , vol.55
    • Markman, M.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.